HK Stock Market Move | AKESO-B(09926) rose more than 6% in early trading as it collaborates with the US-based INOVIO in exploring innovative treatments for glioblastoma using new DNA drugs.

AKESO-B (09926) rose by more than 6% in the early trading session, and as of the time of writing, it is up 6.3% to 101.3 Hong Kong dollars, with a trading volume of 3.43 billion Hong Kong dollars. In terms of news, AKESO and INOVIO jointly announced that they have reached a cooperation agreement with the world's top cancer research institution Dana Farber Cancer Institute and the leading medical group Mass General Brigham, to jointly explore AKESO's global first-in-class PD-1/CTLA-4 bispecific antibody cardineli in combination with INOVIO's DNA drug INO-5412 for the innovative treatment of glioblastoma (GBM). Dr. Xia Yu, founder, chairman, president and chief executive officer of AKESO, stated that cardineli is the world's first approved and marketed dual-antibody cancer immunotherapy. AKESO is accelerating the global development of cardineli through a diversified approach of "independent development + global collaboration", deeply exploring the breakthrough clinical value and international role of cardineli as an immune combination cornerstone drug, and promoting the development of cancer immunotherapy in the era of 2.0.